Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Shared recognition of citrullinated tenascin-C peptides by T and B cells in rheumatoid arthritis
Jing Song, … , Eddie A. James, Jane H. Buckner
Jing Song, … , Eddie A. James, Jane H. Buckner
Published January 28, 2021
Citation Information: JCI Insight. 2021;6(5):e145217. https://doi.org/10.1172/jci.insight.145217.
View: Text | PDF
Research Article Immunology

Shared recognition of citrullinated tenascin-C peptides by T and B cells in rheumatoid arthritis

  • Text
  • PDF
Abstract

Tenascin-C (TNC), an extracellular matrix protein that has proinflammatory properties, is a recently described antibody target in rheumatoid arthritis (RA). In this study, we utilized a systematic discovery process and identified 5 potentially novel citrullinated TNC (cit-TNC) T cell epitopes. CD4+ T cells specific for these epitopes were elevated in the peripheral blood of subjects with RA and showed signs of activation. Cit-TNC–specific T cells were also present among synovial fluid T cells and secreted IFN-γ. Two of these cit-TNC T cell epitopes were also recognized by antibodies within the serum and synovial fluid of individuals with RA. Detectable serum levels of cit-TNC–reactive antibodies were prevalent among subjects with RA and positively associated with cyclic citrullinated peptide (CCP) reactivity and the HLA shared epitope. Furthermore, cit-TNC–reactive antibodies were correlated with rheumatoid factor and elevated in subjects with a history of smoking. This work confirms cit-TNC as an autoantigen that is targeted by autoreactive CD4+ T cells and autoantibodies in patients with RA. Furthermore, our findings raise the possibility that coinciding epitopes recognized by both CD4+ T cells and B cells have the potential to amplify autoimmunity and promote the development and progression of RA.

Authors

Jing Song, Anja Schwenzer, Alicia Wong, Sara Turcinov, Cliff Rims, Lorena Rodriguez Martinez, David Arribas-Layton, Christina Gerstner, Virginia S. Muir, Kim S. Midwood, Vivianne Malmström, Eddie A. James, Jane H. Buckner

×

Figure 5

Anti–cit-TNC antibodies do not cross-react with each other.

Options: View larger image (or click on image) Download as PowerPoint
Anti–cit-TNC antibodies do not cross-react with each other.
Sera that we...
Sera that were double-reactive with peptides cit-TNC17 or cit-TNC56 and cit-TNC56, cit-TNC17, or cit-TNC5 were diluted 1:100, incubated with 1, 10, and 100 μg/mL of peptides for 2 hours and centrifuged at 10,000g for 10 minutes, and the supernatant then added to peptide-coated plates for analysis by ELISA. (A) No cross-reactivity between anti–cit-TNC17 and both anti–cit-TNC56 and anti–cit-TNC5. (B) Limited cross-reactivity between anti–cit-TNC56 and both anti–cit-TNC17 and anti–cit-TNC5. Each panel was run on a separate plate.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts